Get the Stockscreener App
0.7739
9.15%
0.0649
After Hours:
.77
-0.0039
-0.50%
Lexaria Bioscience Corp stock is traded at $0.7739, with a volume of 95,786.
It is up +9.15% in the last 24 hours and up +16.90% over the past month.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
See More
Previous Close:
$0.709
Open:
$0.71
24h Volume:
95,786
Relative Volume:
0.16
Market Cap:
$19.26M
Revenue:
$522.00K
Net Income/Loss:
$-10.80M
P/E Ratio:
-1.3473
EPS:
-0.5744
Net Cash Flow:
$-8.78M
1W Performance:
+7.71%
1M Performance:
+16.90%
6M Performance:
-24.86%
1Y Performance:
-43.92%
1-Day Range:
$0.6779
$0.7825
1-Week Range:
$0.6349
$0.7825
52-Week Range:
$0.46
$1.8955
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.7739 | 17.65M | 522.00K | -10.80M | -8.78M | -0.5744 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Lexaria launches 2026 research program for drug delivery tech - Investing.com Nigeria
Lexaria launches 2026 research program for drug delivery tech By Investing.com - Investing.com Australia
Lexaria Announces New R&D Plans for 2026 - Investing News Network
Lexaria Launches 2026 R&D Push to Advance GLP-1 and Cannabidiol Drug Delivery - TipRanks
LEXX Initiates 2026 R&D Program to Enhance Pharma Innovations - GuruFocus
Biotech tests new oral GLP-1 formulas against Wegovy tablets - Stock Titan
Update Recap: Will Smith Douglas Homes Corp benefit from rate cuts2025 Big Picture & Long Hold Capital Preservation Plans - baoquankhu1.vn
Is Lexaria Bioscience Corp. exposed to currency risksMarket Performance Recap & Technical Pattern Alert System - mfd.ru
Lexaria Bioscience: Improving Oral Weight-Loss Drug Tolerability - The Globe and Mail
Aug Wrap: Is Lexaria Bioscience Corp a strong candidate for buy and holdEarnings Recap Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Lexaria Bioscience: Oral Drug Delivery Technology Targets Next-Gen Weight Loss Market - The Globe and Mail
LEXX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
LEXX Should I Buy - Intellectia AI
Aug Intraday: Can Lexaria Bioscience Corp expand into new marketsJuly 2025 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
US Market Wrap: What are the risks of holding Hanover Bancorp IncMarket Growth Summary & Safe Capital Allocation Plans - baoquankhu1.vn
Update Report: Can Lexaria Bioscience Corp Equity Warrant sustain earnings growth2025 Dividend Review & Low Risk Investment Opportunities - baoquankhu1.vn
Published on: 2026-02-20 23:25:19 - baoquankhu1.vn
Will Lexaria Bioscience Corp. Equity Warrant stock go up in YEARJuly 2025 Selloffs & Entry Point Confirmation Signals - mfd.ru
Published on: 2026-02-20 04:22:15 - baoquankhu1.vn
Aug Intraday: Is Lexaria Bioscience Corp exposed to currency risksJuly 2025 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Aug Action: Will NHICU outperform tech stocksDip Buying & Verified Short-Term Trading Plans - baoquankhu1.vn
Is Lexaria Bioscience Corp. likely to announce a buyback2025 Support & Resistance & Entry Point Strategy Guides - mfd.ru
How Lexaria Bioscience Corp. Equity Warrant stock performs in interest rate cyclesQuarterly Earnings Summary & AI Optimized Trade Strategies - mfd.ru
Why Lexaria Bioscience Corp. stock could rally in 2025July 2025 Update & Real-Time Market Trend Scan - mfd.ru
Can Lexaria Bioscience Corp. ride the EV wave2025 AllTime Highs & AI Powered Market Entry Strategies - mfd.ru
Will Lexaria Bioscience Corp. stock attract ESG investorsMarket Trend Report & Entry and Exit Point Strategies - mfd.ru
LEXX PE Ratio & Valuation, Is LEXX Overvalued - Intellectia AI
Aug Momentum: Can Lexaria Bioscience Corp. Equity Warrant stock outperform in 2025 bull marketWatch List & AI Optimized Trading Strategy Guides - mfd.ru
Can Lexaria Bioscience Corp. Equity Warrant sustain earnings growthJuly 2025 PostEarnings & Low Risk High Win Rate Stock Picks - mfd.ru
Research Analysts Set Expectations for LEXX Q2 Earnings - Defense World
Analysts Set Expectations for LEXX FY2028 Earnings - Defense World
Is Lexaria Bioscience Corp. Equity Warrant exposed to political riskRecession Risk & AI Driven Stock Price Forecasts - mfd.ru
Quarterly Earnings: Is Lexaria Bioscience Corp a strong candidate for buy and holdMarket Growth Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Lexaria Bioscience Stock Price, News, Quote & History - Investing News Network
Bear Alert: Can Lexaria Bioscience Corp expand into new markets2025 Market WrapUp & Weekly Top Gainers Trade List - baoquankhu1.vn
Aug Swings: What is Lexaria Bioscience Corp Equity Warrants revenue forecastJuly 2025 Spike Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Hedge Fund Moves: Does Lexaria Bioscience Corp have declining or rising EPSWeekly Stock Recap & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Lexaria Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Lexaria’s Oral Liraglutide Shows Comparable Performance and Fewer Side Effects in Human Study - TipRanks
Lexaria Bioscience (LEXX) Demonstrates Promising Results in Late - GuruFocus
Lexaria Announces Positive Final Results from Human Pilot Study #5 - Investing News Network
Lexaria Announces Positive Final Results From Human Pilot Study #5 - The Joplin Globe
Experimental liraglutide pill shows similar results, 67% less nausea - Stock Titan
Signal Recap: Does Lexaria Bioscience Corp offer margin of safetyPortfolio Return Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
Aug Outlook: What is Lexaria Bioscience Corp. Equity Warrant s revenue forecastBreakout Watch & Fast Gaining Stock Reports - baoquankhu1.vn
Aug Levels: Can Lexaria Bioscience Corp sustain its profitabilityJuly 2025 Reactions & Accurate Entry/Exit Alerts - baoquankhu1.vn
Jobs Data: Will Lexaria Bioscience Corp Equity Warrant stock go up in YEAR2025 Growth vs Value & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Portfolio Recap: Is Lexaria Bioscience Corp Equity Warrant currently under institutional pressureJuly 2025 Volume & Weekly Return Optimization Plans - baoquankhu1.vn
Aug Sectors: Is Lexaria Bioscience Corp exposed to political riskWeekly Trading Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):